CClinicalTrials.gg
Sign In
CompletedNCT00517426Updated Jan 28, 2016

Effects of Acetazolamide and CO2 Inhalation on Exercise-induced Periodic Breathing in Heart Failure

A Phase 4 interventional study of acetazolamide in Chronic Heart Failure, sponsored by Centro Cardiologico Monzino. Completed at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-01-28.

Sponsored by Centro Cardiologico Monzino · Phase 4 and Interventional

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To evaluate the effects of CO2 inhalation and acetazolamide treatment on exercise-induced periodic breathing in patients with chronic stable heart failure.

Patients will be given CO2 (2%) during a constant workload exercise. Patients will be also evaluated by maximal cardiopulmonary exercise test without and with acetazolamide acute and chronic treatment.

02

Conditions studied

  • Chronic Heart Failure

Browse trials for

Keywords

  • heart failure,
  • exercise
  • periodic breathing,
  • acetazolamide
03

In context

Heart Failure

5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.

This study's enrollment of 20 is below the median of 72 across 3,736 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Centro Cardiologico Monzino is the lead sponsor of 69 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • chronic heart failure in stable clinical condition
  • exercise-induced periodic breathing

Exclusion criteria

Exclusion Criteria:

  • comorbidities
  • NYHA class IV
05

Study design

Phase
Phase 4
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Active Acetazolamide

    Drug: acetazolamide

Interventions

  • Drugacetazolamide

    i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days

    Also known as: Diamox

06

What researchers measure

Primary outcomes

  1. Suppression of periodic breathing

    Time frame: two days

Secondary outcomes

  1. suppression of sleeping apnea

    Time frame: two days

07

Study locations

1 site
  • Centro Cardiologico Monzino, University of Milan
    Milan, 20138, Italy
08

References and documents

Publications

  • Agostoni P, Bussotti M, Cattadori G, Margutti E, Contini M, Muratori M, Marenzi G, Fiorentini C. Gas diffusion and alveolar-capillary unit in chronic heart failure. Eur Heart J. 2006 Nov;27(21):2538-43. doi: 10.1093/eurheartj/ehl302. Epub 2006 Oct 6. PubMed 17028107 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00517426
Lead sponsor
Centro Cardiologico Monzino
Responsible party
Piergiuseppe Agostoni (MD PhD, Centro Cardiologico Monzino) — Principal investigator
First posted
Aug 17, 2007
Start date
Jul 2007
Primary completion
Jul 2011
Completion
Aug 2012
Last update
Jan 28, 2016

Study contacts

Piergiuseppe Agostoni, MD, PhD
principal investigator · Centro Cardiologico Monzino

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Heart Failure→

Other studies from this sponsor

Centro Cardiologico Monzino

Start the discussion